logo
Share SHARE
FONT-SIZE Plus   Neg

Lilly : Late-stage Lung Cancer Trial Meets Primary Endpoint Of Overall Survival

Eli Lilly and Co. (LLY: Quote) announced Wednesday that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer or NSCLC, showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel.

REVEL also showed a statistically significant improvement in progression-free survival in the ramucirumab arm compared to the control arm.

The global, randomized, double-blind REVEL trial compared ramucirumab and docetaxel to placebo and docetaxel in NSCLC patients whose disease has progressed after failure of prior platinum-based chemotherapy for locally advanced or metastatic disease. The study included nonsquamous and squamous NSCLC patients. The most common (>5% incidence) Grade >3 adverse events occurring at a higher rate on the ramucirumab-plus-docetaxel arm compared to the control arm were decreased white blood cell count (neutropenia/leukopenia), febrile neutropenia, fatigue/asthenia and hypertension.

Lilly said it plans to present data from the REVEL trial at an upcoming scientific meeting and intends to submit the first application of these data to regulatory authorities in 2014.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Automakers on Friday reported higher U.S. vehicle sales for the month of April, helped by low gasoline prices as well as continuing strong demand for trucks and utility vehicles. General Motors Co. and FCA US, LLC each reported sales growth of about 6% for the month, while Ford Motor Co. and Toyota Motor Corp. reported 5.4% and 1.8% increases, respectively. Are you really ready for an objective appraisal of how old you look? If not, stay far away from How-Old.net, a website to guess how old you are, which was introduced at the recent Microsoft Build 2015 developer conference. The website has caught... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its first quarter loss widened from last year, as higher costs and expenses more than offset a 35% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
RELATED NEWS
Trade LLY now with 
Follow RTT